Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Asset Resilience Ratio
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has an Asset Resilience Ratio of -0.13% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002864 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's Asset Resilience Ratio has changed over time. See Shaanxi Panlong Pharmaceutical Group Lim (002864) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Shaanxi Panlong Pharmaceutical Group Lim worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-2.77 Million | -0.13% |
| Total Liquid Assets | CN¥-2.77 Million | -0.13% |
Asset Resilience Insights
- Limited Liquidity: Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A maintains only -0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2019–2023)
The table below shows the annual Asset Resilience Ratio data for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.13% | CN¥-2.87 Million ≈ $-419.60K |
CN¥2.13 Billion ≈ $310.96 Million |
+0.47pp |
| 2022-12-31 | -0.61% | CN¥-11.77 Million ≈ $-1.72 Million |
CN¥1.93 Billion ≈ $282.53 Million |
-0.72pp |
| 2021-12-31 | 0.11% | CN¥1.48 Million ≈ $217.12K |
CN¥1.33 Billion ≈ $194.65 Million |
-5.29pp |
| 2019-12-31 | 5.41% | CN¥50.21 Million ≈ $7.35 Million |
CN¥928.88 Million ≈ $135.92 Million |
-- |
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chine… Read more